HERCEPTIN HYLECTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HERCEPTIN HYLECTA (HERCEPTIN HYLECTA).
HERCEPTIN HYLECTA is a combination of trastuzumab, a humanized anti-HER2 monoclonal antibody, and hyaluronidase, an endoglycosidase that degrades hyaluronan to increase tissue permeability and enhance subcutaneous absorption. Trastuzumab binds to the extracellular domain of HER2, inhibiting downstream signaling pathways (PI3K/AKT and MAPK), leading to antibody-dependent cellular cytotoxicity (ADCC) and inhibition of cell proliferation.
| Metabolism | Trastuzumab is a monoclonal antibody; metabolism is primarily via catabolism into small peptides and amino acids. Hyaluronidase is locally degraded by hyaluronidases and proteases. |
| Excretion | Renal clearance is minimal; trastuzumab is primarily eliminated via intracellular catabolism into peptides and amino acids. Fecal excretion is negligible. |
| Half-life | The terminal elimination half-life is approximately 28–38 days. This long half-life supports a 3-week dosing interval and allows for prolonged target suppression. |
| Protein binding | Approximately 95% bound, primarily to endogenous immunoglobulins and albumin via FcRn recycling, contributing to the extended half-life. |
| Volume of Distribution | The volume of distribution is approximately 3.0 L/kg, indicating extensive distribution into tissues, including tumor tissue expressing HER2 receptors. |
| Bioavailability | Subcutaneous: approximately 93% relative to intravenous administration, allowing for fixed-dose administration without a loading dose. |
| Onset of Action | Subcutaneous: Time to objective response varies, but pharmacodynamic effects (HER2 receptor blockade) are measurable within days; clinical response typically observed after 2–4 weeks. |
| Duration of Action | The therapeutic effect persists for several weeks after a single dose, correlating with serum concentrations above therapeutic thresholds. Dosing every 3 weeks maintains continuous receptor occupancy. |
Subcutaneous injection over 2-5 minutes: Loading dose of 600 mg (given subcutaneously over approximately 5 minutes) followed by 600 mg every 3 weeks. Two fixed-dose vials of 600 mg/5 mL are used for each dose.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; however, use caution in patients with severe renal impairment (CrCl <30 mL/min) as safety data are limited. |
| Liver impairment | No formal dose adjustment recommended; use caution in patients with hepatic impairment due to limited data. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required for elderly patients; clinical studies included patients aged ≥65 years with no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HERCEPTIN HYLECTA (HERCEPTIN HYLECTA).
| Breastfeeding | No data on trastuzumab or hyaluronidase in human milk. Trastuzumab is a large IgG molecule likely to be secreted in low amounts; M/P ratio unknown. Because of potential adverse effects, breastfeeding is not recommended during therapy and for 7 months after last dose. |
| Teratogenic Risk | Pregnancy Category D. Trastuzumab is associated with oligohydramnios, fetal renal failure, anuria, pulmonary hypoplasia, and fetal death. Risk is highest in second and third trimesters due to interference with fetal nephrogenesis and organ development. Hyaluronidase component is not associated with teratogenicity. |
■ FDA Black Box Warning
Boxed Warning: Cardiomyopathy – Trastuzumab administration can result in subclinical and clinical cardiac failure. The incidence and severity were highest in patients receiving trastuzumab concurrently with anthracycline-containing chemotherapy. Assess left ventricular ejection fraction (LVEF) prior to initiation and monitor frequently during therapy. Discontinue for cardiomyopathy.
| Serious Effects |
None known.
| Precautions | ["Cardiomyopathy: Monitor LVEF at baseline and every 3 months during and after therapy.","Infusion reactions: May be severe or fatal, particularly with rapid infusion.","Pulmonary toxicity: Interstitial lung disease including pneumonitis, acute respiratory distress syndrome.","Embryo-fetal toxicity: Exposure during pregnancy can cause oligohydramnios and fetal harm; advise effective contraception."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal cardiac function (LVEF) at baseline and every 3 months during therapy and after delivery if continued. Perform serial fetal ultrasound for oligohydramnios and fetal renal development (echogenic kidneys, renal volume) every 4 weeks after 20 weeks gestation. Assess amniotic fluid index. Monitor fetal growth. Evaluate newborn for signs of nephrotoxicity and pulmonary hypoplasia. |
| Fertility Effects | Trastuzumab may impair fertility in females based on animal studies showing reduced ovarian function. No human data on reversibility. Hyaluronidase is not expected to affect fertility. |